Skip to content
value.today

Urovant Sciences: peers

Change the peers

Urovant Sciences beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Urovant Sciences, Contineum Therapeutics, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Urovant Sciences, Regenxbio Inc., Indaptus Therapeutics, Inc., Puma Biotechnology, Inc., Phathom Pharmaceuticals, Inc., CytomX Therapeutics, Inc., Cypherpunk Technologies Inc., Contineum Therapeutics, Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureUrovant Sciencesbase
UROV · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Regenxbio Inc.
RGNX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Indaptus Therapeutics, Inc.
INDP · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Puma Biotechnology, Inc.
PBYI · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Phathom Pharmaceuticals, Inc.
PHAT · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
CytomX Therapeutics, Inc.
CTMX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Cypherpunk Technologies Inc.
CYPH · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Contineum Therapeutics, Inc.
CTNM · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$512 Mlast known, Jan 1, 2021 · Market dataLast known value: no current one4th of 8$513 MOct 6, 2026 · Market data2nd of 8$513 MOct 30, 2026 · Market data3rd of 8$508 MOct 19, 2026 · Market data5th of 8$506 MOct 30, 2026 · Market data6th of 8$504 MOct 28, 2026 · Market data7th of 8$493 MOct 30, 2026 · Market data8th of 8$534 MAug 1, 2026 · Market data1st of 8$510 M8 ranked
Revenue (Better neither way: ranked highest first)——$170 MFY2025 · SEC3rd of 4——$228 MFY2025 · SEC1st of 4$175 MFY2025 · SEC2nd of 4$76 MFY2025 · SEC4th of 4————$173 M4 ranked
Net income (Higher is better)——$-194 MFY2025 · SEC6th of 7$-21 MFY2025 · SEC4th of 7$31 MFY2025 · SEC1st of 7$-221 MFY2025 · SEC7th of 7$-17 MFY2025 · SEC3rd of 7$5 MFY2025 · SEC2nd of 7$-60 MFY2025 · SEC5th of 7$-21 M7 ranked
Employees (Better neither way: ranked highest first)——372As on 2021 · Profile1st of 5————77As on 2021 · Profile2nd of 569December 31, 2025 · Profile3rd of 56December 31, 2025 · Profile5th of 551December 31, 2025 · Profile4th of 5695 ranked
Growth
Revenue growth (Higher is better)————+104.5%FY2025 · SEC2nd of 492nd96th————-0.9%FY2025 · SEC3rd of 424th27th+216.9%FY2025 · SEC1st of 496th98th-44.8%FY2025 · SEC4th of 45th2nd————————+51.8%4 ranked
Revenue growth, 3 years a year (Higher is better)————+14.8%FY2025 · SEC1st of 364th79th————+0.1%FY2025 · SEC3rd of 327th33rd————+12.8%FY2025 · SEC2nd of 360th75th————————+12.8%3 ranked
Earnings per share growth (Higher is better)————————————-1.6%FY2025 · SEConly one with it34th36th————————————————-1.6%—
Margins and returns
Gross margin (Higher is better)————————————74.5%FY2025 · SEC2nd of 273rd87th87.1%FY2025 · SEC1st of 288th95th————————————80.8%2 ranked
Operating margin (Higher is better)————-94.6%FY2025 · SEC4th of 424th11th————16.3%FY2025 · SEC1st of 483rd80th-91.4%FY2025 · SEC3rd of 424th11th-29.3%FY2025 · SEC2nd of 438th19th————————-60.4%4 ranked
Net margin (Higher is better)————-113.8%FY2025 · SEC3rd of 421st9th————13.6%FY2025 · SEC1st of 484th82nd-126.3%FY2025 · SEC4th of 420th9th-22.8%FY2025 · SEC2nd of 441st20th————————-68.3%4 ranked
Free cash flow margin (Higher is better)————-74.1%FY2025 · SEC2nd of 424th10th————18.3%FY2025 · SEC1st of 485th86th-95.4%FY2025 · SEC3rd of 423rd9th-99.5%FY2025 · SEC4th of 422nd8th————————-84.8%4 ranked
Return on equity (Higher is better)————-107.0%FY2025 · SEC5th of 623rd10th-588.1%FY2025 · SEC6th of 61st1st28.0%FY2025 · SEC1st of 694th90th————-35.3%FY2025 · SEC4th of 651st22nd5.1%FY2025 · SEC2nd of 676th51st-26.1%FY2025 · SEC3rd of 657th25th-30.7%6 ranked
Return on invested capital (Higher is better)————————————30.3%FY2025 · SEConly one with it87th88th————————————————30.3%—
Valuation
P/E ratio (Better neither way: ranked highest first)————————————21.3×price Oct 19, 2026 · Market dataonly one with it34th56th————————————————21.3×—
Price to sales (Better neither way: ranked highest first)————3.3×price Oct 6, 2026 · Market data3rd of 547th65th————2.2×price Oct 19, 2026 · Market data4th of 536th51st1.8×price Oct 30, 2026 · Market data5th of 531st46th6.6×price Oct 28, 2026 · Market data2nd of 564th83rd328.9×price Oct 30, 2026 · Market data1st of 598th99th————3.3×5 ranked
Price to book (Better neither way: ranked highest first)————5.0×price Oct 6, 2026 · Market data3rd of 566th76th162.9×price Oct 30, 2026 · Market data1st of 599th100th3.9×price Oct 19, 2026 · Market data4th of 559th70th————5.1×price Oct 28, 2026 · Market data2nd of 567th77th3.2×price Oct 30, 2026 · Market data5th of 551st64th2.0×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price5.0×5 ranked
Free cash flow yield (Higher is better)————-24.6%price Oct 6, 2026 · Market data5th of 629th13th-2.2%price Oct 30, 2026 · Market data2nd of 661st32nd8.2%price Oct 19, 2026 · Market data1st of 693rd81st-33.0%price Oct 30, 2026 · Market data6th of 625th11th-15.1%price Oct 28, 2026 · Market data4th of 637th17th-5.5%price Oct 30, 2026 · Market data3rd of 653rd26th-10.4%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price-10.3%6 ranked
Financial strength
Debt to equity (Lower is better)————————————0.2×FY2025 · SEConly one with it30th20th————————————————0.2×—
Net debt to EBITDA (Lower is better)————————————-0.1×FY2025 · SEConly one with it24th16th————————————————-0.1×—
Piotroski F-score (Higher is better)——————7 of 9FY2025 · SEC1st of 24 of 9FY2025 · SEC2nd of 2——————5.5 of 92 ranked
Scorecard
Scorecard (Higher is better)——6 of 19FY2025 · Scorecard2nd of 71 of 12FY2025 · Scorecard7th of 712 of 24FY2025 · Scorecard1st of 73 of 15FY2025 · Scorecard5th of 76 of 19FY2025 · Scorecard2nd of 74 of 13FY2025 · Scorecard4th of 71 of 6FY2025 · Scorecard6th of 731% passed7 ranked
Valuation checks (Higher is better)——1 of 5FY2025 · Scorecard2nd of 60 of 4FY2025 · Scorecard5th of 62 of 6FY2025 · Scorecard1st of 61 of 5FY2025 · Scorecard2nd of 61 of 5FY2025 · Scorecard2nd of 60 of 5FY2025 · Scorecard5th of 6——20% passed6 ranked
Growth checks (Higher is better)——3 of 5FY2025 · Scorecard2nd of 70 of 2FY2025 · Scorecard6th of 71 of 6FY2025 · Scorecard5th of 71 of 3FY2025 · Scorecard4th of 72 of 5FY2025 · Scorecard3rd of 72 of 2FY2025 · Scorecard1st of 70 of 1FY2025 · Scorecard6th of 733% passed7 ranked
Profitability checks (Higher is better)——1 of 5FY2025 · Scorecard4th of 70 of 3FY2025 · Scorecard5th of 75 of 6FY2025 · Scorecard1st of 70 of 3FY2025 · Scorecard5th of 72 of 5FY2025 · Scorecard2nd of 71 of 3FY2025 · Scorecard3rd of 70 of 2FY2025 · Scorecard5th of 720% passed7 ranked
Financial health checks (Higher is better)——1 of 3FY2025 · Scorecard5th of 71 of 2FY2025 · Scorecard2nd of 74 of 5FY2025 · Scorecard1st of 71 of 3FY2025 · Scorecard5th of 71 of 3FY2025 · Scorecard5th of 71 of 2FY2025 · Scorecard2nd of 71 of 2FY2025 · Scorecard2nd of 750% passed7 ranked
Shareholder returns checks (Higher is better)——0 of 1FY2025 · Scorecard1st of 70 of 1FY2025 · Scorecard1st of 70 of 1FY2025 · Scorecard1st of 70 of 1FY2025 · Scorecard1st of 70 of 1FY2025 · Scorecard1st of 70 of 1FY2025 · Scorecard1st of 70 of 1FY2025 · Scorecard1st of 70% passed7 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)——82.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 70.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 778.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 786.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 799.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 719.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 799.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 782.1%7 ranked
Institutions holding (Better neither way: ranked highest first)——1742026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 7212026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 71572026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 71612026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 71942026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7772026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 71182026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 71577 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)——-18.4 pp2026-Q2 against 2026-Q1 · 13F6th of 6-2.9 pp2026-Q2 against 2026-Q1 · 13F5th of 6+0.5 pp2026-Q2 against 2026-Q1 · 13F4th of 6+2.4 pp2026-Q2 against 2026-Q1 · 13F3rd of 6+9.2 pp2026-Q2 against 2026-Q1 · 13F1st of 6+5.5 pp2026-Q2 against 2026-Q1 · 13F2nd of 6——+1.5 pp6 ranked

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Urovant Sciences: How market caps are worked out; Regenxbio Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Indaptus Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Puma Biotechnology, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Phathom Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; CytomX Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Cypherpunk Technologies Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Contineum Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Urovant Sciences———
Regenxbio Inc.-94.6%FY2025
24th percentile in Healthcaremedian -7.7%, 674 companies
11th percentile in USAmedian 3.5%, 2,594 companies
Indaptus Therapeutics, Inc.———
Puma Biotechnology, Inc.16.3%FY2025
83rd percentile in Healthcaremedian -7.7%, 674 companies
80th percentile in USAmedian 3.5%, 2,594 companies
Phathom Pharmaceuticals, Inc.-91.4%FY2025
24th percentile in Healthcaremedian -7.7%, 674 companies
11th percentile in USAmedian 3.5%, 2,594 companies
CytomX Therapeutics, Inc.-29.3%FY2025
38th percentile in Healthcaremedian -7.7%, 674 companies
19th percentile in USAmedian 3.5%, 2,594 companies
Cypherpunk Technologies Inc.———
Contineum Therapeutics, Inc.———

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$68 M$136 M$204 M$272 M201420152016201720182019202020212022202320242025Regenxbio Inc. $170 MPuma Biotechnology, Inc. $228 MPhathom Pharmaceuticals, Inc. $175 MCytomX Therapeutics, Inc. $76 MCypherpunk Technologies Inc. $2 M

Rank in the group

1st2nd3rd4th5th2013201420152016201720182019202020212022202320242025Regenxbio Inc.: 1st of 2 in 2013Regenxbio Inc.: 1st of 2 in 2014Regenxbio Inc.: 2nd of 2 in 2015Regenxbio Inc.: 2nd of 2 in 2016Regenxbio Inc.: 2nd of 2 in 2017Regenxbio Inc.: 2nd of 3 in 2018Regenxbio Inc.: 2nd of 4 in 2020Regenxbio Inc.: 2nd of 3 in 2022Regenxbio Inc.: 3rd of 5 in 2023Regenxbio Inc.: 3rd of 4 in 2024Regenxbio Inc.: 3rd of 4 in 2025Regenxbio Inc.Puma Biotechnology, Inc.: 1st of 3 in 2018Puma Biotechnology, Inc.: 1st of 2 in 2019Puma Biotechnology, Inc.: 1st of 4 in 2020Puma Biotechnology, Inc.: 1st of 3 in 2021Puma Biotechnology, Inc.: 1st of 3 in 2022Puma Biotechnology, Inc.: 1st of 5 in 2023Puma Biotechnology, Inc.: 1st of 4 in 2024Puma Biotechnology, Inc.: 1st of 4 in 2025Puma Biotechnology, Inc.Phathom Pharmaceuticals, Inc.: 5th of 5 in 2023Phathom Pharmaceuticals, Inc.: 4th of 4 in 2024Phathom Pharmaceuticals, Inc.: 2nd of 4 in 2025Phathom Pharmaceuticals, ICytomX Therapeutics, Inc.: 2nd of 2 in 2013CytomX Therapeutics, Inc.: 2nd of 2 in 2014CytomX Therapeutics, Inc.: 1st of 2 in 2015CytomX Therapeutics, Inc.: 1st of 2 in 2016CytomX Therapeutics, Inc.: 1st of 2 in 2017CytomX Therapeutics, Inc.: 3rd of 3 in 2018CytomX Therapeutics, Inc.: 2nd of 2 in 2019CytomX Therapeutics, Inc.: 3rd of 4 in 2020CytomX Therapeutics, Inc.: 2nd of 3 in 2021CytomX Therapeutics, Inc.: 3rd of 3 in 2022CytomX Therapeutics, Inc.: 2nd of 5 in 2023CytomX Therapeutics, Inc.: 2nd of 4 in 2024CytomX Therapeutics, Inc.: 4th of 4 in 2025CytomX Therapeutics, Inc.Cypherpunk Technologies Inc.: 4th of 4 in 2020Cypherpunk Technologies Inc.: 3rd of 3 in 2021Cypherpunk Technologies InContineum Therapeutics, Inc.: 4th of 5 in 2023Contineum Therapeutics, In
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearUrovant SciencesRegenxbio Inc.Indaptus Therapeutics, Inc.Puma Biotechnology, Inc.Phathom Pharmaceuticals, Inc.CytomX Therapeutics, Inc.Cypherpunk Technologies Inc.Contineum Therapeutics, Inc.
2025—$170 MSEC3rd—$228 MSEC1st$175 MSEC2nd$76 MSEC4th——
2024—$83 MSEC3rd—$230 MSEC1st$55 MSEC4th$138 MSEC2nd——
2023—$90 MSEC3rd—$236 MSEC1st$1 MSEC5th$101 MSEC2nd—$50 MSEC4th
2022—$113 MSEC2nd—$228 MSEC1st—$53 MSEC3rd——
2021———$253 MSEC1st—$37 MSEC2nd$2 MSEC3rd—
2020—$155 MSEC2nd—$225 MSEC1st—$68 MSEC3rd$2 MSEC4th—
2019———$272 MSEC1st—$27 MSEC2nd——
2018—$219 MSEC2nd—$251 MSEC1st—$60 MSEC3rd——
2017—$10 MSEC2nd———$72 MSEC1st——
2016—$5 MSEC2nd———$15 MSEC1st——
2015—$8 MSEC2nd———$8 MSEC1st——
2014—$6 MSEC1st———$5 MSEC2nd——

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Urovant Sciences#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Regenxbio Inc.RGNX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $513 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $513 M (Oct 6, 2026) · revenue $170 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Indaptus Therapeutics, Inc.INDP · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $513 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $513 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Puma Biotechnology, Inc.PBYI · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $508 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $508 M (Oct 19, 2026) · revenue $228 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Phathom Pharmaceuticals, Inc.PHAT · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $506 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $506 M (Oct 30, 2026) · revenue $175 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • CytomX Therapeutics, Inc.CTMX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $504 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $504 M (Oct 28, 2026) · revenue $76 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Cypherpunk Technologies Inc.CYPH · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $493 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $493 M (Oct 30, 2026) · revenue $2 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Contineum Therapeutics, Inc.CTNM · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $534 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $534 M (Aug 1, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Monopar Therapeutics Inc.MNPR · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $487 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $487 M (Oct 28, 2026) · revenue $0 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Arvinas, Inc.ARVN · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $544 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $544 M (Sep 18, 2026) · revenue $263 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Surrozen, Inc.SRZN · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $562 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $562 M (Oct 30, 2026) · revenue $3 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add
  • MapLight Therapeutics, Inc.MPLT · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $558 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $558 M (Sep 15, 2026)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add
  • DiaMedica Therapeutics Inc.DMAC · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $469 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $469 M (Oct 28, 2026)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.